This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Garnero P (2006) Biochemical markers in osteoarthritis: will they measure up? Nat Clin Pract Rheumatol 2: 116–117
Lohmander LS and Eyre DR (2005) From biomarker to surrogate outcome in osteoarthritis—what are the challenges? J Rheumatol 32: 1142–1143
Mazzuca SA et al. (2006) Urinary levels of type II collagen C–telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis. Ann Rheum Dis 65: 1055–1059
Mitchell PG et al. (2006) Pharmacodynamic modulation of bone-derived and cartilage-derived collagen biomarkers in the ovarectomized rat model. Osteoarthr Cartil 14 [suppl B]: S60
Acknowledgements
The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Lohmander, S. Can treatment with risedronate benefit patients with knee osteoarthritis?. Nat Rev Rheumatol 3, 198–199 (2007). https://doi.org/10.1038/ncprheum0456
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0456
This article is cited by
-
Non-surgical management of early knee osteoarthritis
Knee Surgery, Sports Traumatology, Arthroscopy (2012)
-
Extracellular matrix and pathogenic mechanisms in osteoarthritis
Current Rheumatology Reports (2008)